Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma

NCT03891979 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Suspended due to Primary Investigator's decision

Conditions

Pancreatic Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Ciprofloxacin 500mg PO BID days 1-29
DRUG: Metronidazole 500mg PO TID days 1-29

Sponsor

NYU Langone Health